Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19
McCreary et al., medRxiv, doi:10.1101/2021.11.30.21266756
https://c19early.org/mccreary.html